Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide 1.8 mg vs 0.9 mg in Japanese Type 2 Diabetes
NCT02505334Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2015
- Primary completion
- May 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02505334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505334.